
Opioid Induced Constipation Market by Active Ingredients (Bulk Cathartics, Stimulant Cathartics, Docusate Sodium, Emollient/Lubricant Cathartics), Drug Class (Locally Acting Chloride Channel Activator (LACCA), Non-Selective Opioid Antagonist, Peripherally
Description
Opioid Induced Constipation Market by Active Ingredients (Bulk Cathartics, Stimulant Cathartics, Docusate Sodium, Emollient/Lubricant Cathartics), Drug Class (Locally Acting Chloride Channel Activator (LACCA), Non-Selective Opioid Antagonist, Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)), Mode of Administration, Distribution Channel - Global Forecast 2024-2030
The Opioid Induced Constipation Market size was estimated at USD 65.95 million in 2023 and expected to reach USD 70.10 million in 2024, at a CAGR 6.69% to reach USD 103.78 million by 2030.
Global Opioid Induced Constipation Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Opioid Induced Constipation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Opioid Induced Constipation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Opioid Induced Constipation Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Lantheus, Mylan by Viatris Inc., Pfizer, Inc., RedHill Biopharma Inc., Salix Pharmaceuticals by Bausch Health Companies Inc., Shionogo & Co. Ltd., SLA Pharma AG, Synergy Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Opioid Induced Constipation Market to forecast the revenues and analyze trends in each of the following sub-markets:
Active Ingredients
Bulk Cathartics, Stimulant Cathartics
Docusate Sodium
Emollient/Lubricant Cathartics
Lubiprostone
Methylnaltrexone Bromide
Naloxegol
Osmotic laxatives
Prostaglandins/Prokinetic Drugs
Drug Class
Locally Acting Chloride Channel Activator (LACCA)
Non-Selective Opioid Antagonist
Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
μ-Opioid Antagonist
Mode of Administration
Oral
Parenteral
Distribution Channel
Drug Store
Hospital Pharmacies
Independent Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Opioid Induced Constipation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Opioid Induced Constipation Market?
3. What are the technology trends and regulatory frameworks in the Opioid Induced Constipation Market?
4. What is the market share of the leading vendors in the Opioid Induced Constipation Market?
5. Which modes and strategic moves are suitable for entering the Opioid Induced Constipation Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Opioid Induced Constipation Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising geriatric population with constipation complications
- 5.1.1.2. Growing prevalence of kidney disorders
- 5.1.1.3. Surging availability of diversified treatments
- 5.1.2. Restraints
- 5.1.2.1. Stringent approval process and time-consuming
- 5.1.3. Opportunities
- 5.1.3.1. Proliferating use of opioids
- 5.1.3.2. Rise in availability in retail pharmacies
- 5.1.4. Challenges
- 5.1.4.1. Concern regarding opioid tolerance and addiction
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Opioid Induced Constipation Market, by Active Ingredients
- 6.1. Introduction
- 6.2. Bulk Cathartics, Stimulant Cathartics
- 6.3. Docusate Sodium
- 6.4. Emollient/Lubricant Cathartics
- 6.5. Lubiprostone
- 6.6. Methylnaltrexone Bromide
- 6.7. Naloxegol
- 6.8. Osmotic laxatives
- 6.9. Prostaglandins/Prokinetic Drugs
- 7. Opioid Induced Constipation Market, by Drug Class
- 7.1. Introduction
- 7.2. Locally Acting Chloride Channel Activator (LACCA)
- 7.3. Non-Selective Opioid Antagonist
- 7.4. Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
- 7.5. μ-Opioid Antagonist
- 8. Opioid Induced Constipation Market, by Mode of Administration
- 8.1. Introduction
- 8.2. Oral
- 8.3. Parenteral
- 9. Opioid Induced Constipation Market, by Distribution Channel
- 9.1. Introduction
- 9.2. Drug Store
- 9.3. Hospital Pharmacies
- 9.4. Independent Pharmacies
- 10. Americas Opioid Induced Constipation Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Opioid Induced Constipation Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Opioid Induced Constipation Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. AstraZeneca PLC
- 14.1.2. Fresenius Kabi AG
- 14.1.3. GlaxoSmithKline PLC
- 14.1.4. Hikma Pharmaceuticals PLC
- 14.1.5. Ironwood Pharmaceuticals, Inc.
- 14.1.6. Lantheus
- 14.1.7. Mylan by Viatris Inc.
- 14.1.8. Pfizer, Inc.
- 14.1.9. RedHill Biopharma Inc.
- 14.1.10. Salix Pharmaceuticals by Bausch Health Companies Inc.
- 14.1.11. Shionogo & Co. Ltd.
- 14.1.12. SLA Pharma AG
- 14.1.13. Synergy Pharmaceuticals Inc.
- 14.1.14. Takeda Pharmaceutical Company Limited
- 14.1.15. Teva Pharmaceutical Industries Ltd.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
- FIGURE 2. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2023 VS 2030
- FIGURE 3. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. OPIOID INDUCED CONSTIPATION MARKET DYNAMICS
- FIGURE 7. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2030 (%)
- FIGURE 8. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 10. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 12. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 14. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.